Brii’s Cocktail Active Against Coronavirus Subvariants, But Will It Succeed On The Market?
The company announced data showing the two-antibody drug had strong activity against Omicron BA.4, BA.5 and BA.2.12.1, but on the US market it would compete against oral drugs.
You may also be interested in...
The company looks to be building momentum at last, with four more late-stage trial readouts expected in the second half of 2022.
Inflation, rising interest rates, market volatility, violence in Ukraine and a persistent pandemic created a chaotic macroenvironment for doing business. Pharma appears poised to grow, nonetheless.
Six months after Brii obtained Chinese approval for its antibody combo for COVID-19, the Beijing joint venture finally launches the drug in China.